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Isoeugenol is a selective 
potentiator of camptothecin 
cytotoxicity in vertebrate cells 
lacking TDP1
Waheba Elsayed1,*, Lamia El-Shafie1,*, Mohamed K. Hassan1,2, Mohamed A. Farag3 & 
Sherif F. El-Khamisy1,4
Camptothecin (CPT), a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor activity against a wide 
range of tumors. Redundancy of TOP1-mediated repair mechanisms is a major challenge facing the 
efficiency of TOP1-targetting therapies. This study aims to uncover new TOP1 targeting approaches 
utilising a selection of natural compounds in the presence or absence of tyrosyl DNA phosphodiesterase 
I (TDP1); a key TOP1-mediated protein-linked DNA break (PDB) repair enzyme. We identify, isoeugenol, 
a phenolic ether found in plant essential oils, as a potentiator of CPT cytotoxicity in Tdp1 deficient but 
not proficient cells. Consistent with our cellular data, isoeugenol did not inhibit Tdp1 enzymatic activity 
in vitro nor it sensitized cells to the PARP1 inhibitor olaparib. However, biochemical analyses suggest 
that isoeugenol inhibits TDP2 catalytic activity; a pathway that can compensate for the absence of 
TDP1. Consistent with this, isoeugenol exacerbated etoposide-induced cytotoxicity, which generates 
TOP2-mediated PDBs for which TDP2 is required for processing. Together, these findings identify 
isoeugenol as a potential lead compound for developing TDP2 inhibitors and encourage structure-
activity relationship studies to shed more light on its utility in drug discovery programs.
Camptothecin (CPT), a quinoline alkaloid isolated from the wood and bark of the Chinese tree Camptotheca 
acuminata, is a well-known topoisomerase I (TOP1) inhibitor1 that was first isolated and identified as an 
anti-cancer agent in 19662. TOP1 functions to relax supercoils by creating a nick in the DNA strand and forming 
a covalent bond between its tyrosyl residue and a 3′ DNA phosphate. An intermediate structure known as TOP1 
cleavage complex (TOP1cc) is formed through cleavage, followed by religation of the DNA strand. CPT acts as 
a cellular poison by reversibly trapping TOP1ccs onto the DNA. TOP1ccs are normally transient; however colli-
sion of replication or transcription machineries with TOP1cc converts them to irreversible protein-linked DNA 
single-strand breaks (SSBs) or double-strand breaks (DSBs)3. Tyrosyl DNA phosphodiesterase I (TDP1) catalyzes 
the hydrolysis of the tyrosyl-3′ phosphate linkage formed between TOP1 and DNA, allowing the rejoining of the 
DNA strand break and hence help cells to overcome CPT-induced cytotoxicity. Mutations of TDP1 lead to the 
autosomal recessive disease SCAN-14. Cell lines derived from patients with SCAN-1 accumulate TOP1-mediated 
protein-linked DNA breaks (PDBs) and were found to be hypersensitive to CPT5.
Owing to CPT’s severe toxicity, other semisynthetic analogues have been developed, namely irinotecan and 
topotecan, which are currently used alone or in combination with other drugs as chemotherapeutic agents6. 
Irinotecan, also known as CPT-11, is approved for colon cancer treatment, whereas topotecan is used for the 
treatment of ovarian cancer. CPT-11 is mainly used for the treatment of metastatic colon cancer as part of a com-
bination regimen alongside 5-fluorouracil. Several studies have demonstrated that combined therapy of two or 
more drugs against cancer cells promotes synergism, enhances therapeutic effectiveness, suppresses drug resist-
ance, and reduces the drug side effects7,8. Functional redundancy in repairing TOP1-mediated PDBs is a potential 
cause for resistance to TOP1-based chemotherapy strategies. Herein, we investigated the cytotoxic effects of 41 
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natural compounds in combination with CPT in the presence or absence of TDP1, with the goal of unraveling 
novel approaches to target TOP1.
We assembled a library of natural derived chemicals that are isolated from either plant or animal origin. 
Natural products provide a vast resource for drug discovery research. For example, in 1971 and as a part of a 
National Cancer Institute program, paclitaxel was identified as the active constituent from a crude extract of the 
bark of Taxus brevifolia9. Paclitaxel is the first taxane to enter clinical trials as a chemotherapeutic agent and is 
used against ovarian, breast, and lung cancers10. Ginkgo biloba extract 761 (EGb761) is another natural compound 
extracted from Ginkgo biloba leaves11 that was proposed to have anti-angiogenic and antioxidant activities.
Our screen yielded a hit compound that appears to be a promising lead as a tyrosyl DNA phosphodiesterase 
II (TDP2) inhibitor. Like TDP1, TDP2 is a tyrosyl DNA phosphodiesterase but that catalyzes the cleavage of 5′ - 
tyrosyl bonds that are present between topoisomerase II (TOP2) and the DNA3. It is known that both enzymes 
while structurally different, can serve as back up for each other in circumstances where one is lacking, but with 
much less efficiency than with their preferred substrate12.
Results
Establishment of sub-lethal concentrations of the library compounds. A selection of 41 diverse 
natural products most of which occur in foods or dietary supplements were subjected to a series of cellular 
and biochemical experiments to identify potential hits to improve TOP1 targeting therapy (Fig. 1A). The large 
therapeutic index reported for these chemicals is encouraging in terms of developing future and safe drugs for 
treatment of cancer. The library is comprised of molecules belonging to different natural products classes viz. 
alkaloids, flavonoids, saponins, terpenes, and phenylpropanoids. To determine sub-lethal doses, the cytotoxic 
effect of each compound was examined at six different concentrations (0.01, 0.1, 1, 5, 10, and 50 μ M) in Tdp1− /− 
DT40 cells (Supplementary Fig. 1). The viability assay used in this study utilizes a blue dye, resazurin, that when 
encountered with viable cells, is reduced to the highly fluorescent red dye resorufin13. The cytotoxicity, therefore, 
is measured as fluorescence intensity quantified by a plate reader. The selected sub-lethal doses (Table 1) were 
then used for the primary screen in combination with a single lethal and three sub-lethal doses of CPT (4, 1, 0.5, 
0.25 nM) in the same cellular model (Supplementary Figs 2 and 3). The combination of any of the compounds 4, 
Figure 1. Isoeugenol potentiates the cytotoxic effect of CPT in a TDP1-dependent manner. (A) A diagram 
summarizing the experimental strategy employed in this study. (B–H) Viability of Tdp1− /− and Tdp1− /− 
DT40 cells complemented with hTDP1 was compared using the indicated doses of camptothecin (CPT) in 
presence or absence of sub-lethal concentrations of compounds 4, 8, 10 , 14, 21, 24 and 33 as indicated in 
Table 1. Results are presented on a semi-log scale and represent the average of 3 biological replicates ± s.e.m. 
Asterisks denote statistical difference (p < 0.001, 4 nM; p < 0.05, 1 nM) using t-test.
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8, 10, 14, 21, 24, or 33 with CPT gave the highest levels of cytotoxicity (viability inhibition) ranged from 81% for 
compound 8 to 47% for compound 24, at the highest concentration of CPT.
Examination of the TOP1-mediated cytotoxic effect in the presence or absence of human 
TDP1. Seven compounds including prunin, isoquercetin, 2,4,4′ trihydroxy chalcone, isoeugenol, xanthohu-
mol, harmine, and thymol (4, 8, 10, 14, 21, 24, 33, resp.) that showed the highest synergistically lethal effect with 
CPT in Tdp1− /− cells were selected for further screening by comparing their effect on chicken DT40 Tdp1− /− 
and an isogeneic control stably expressing human TDP1 (hTDP1) (Fig. 1 and Supplementary Fig. 4). The inten-
sity of fluorescence was normalized to a DMSO control (same volume as that of the highest concentration of 
combined drugs) and the results were obtained from three biological replicates. All tested compounds, except 
compound 14, gave the same effect on both cell lines (Tdp1− /− and Tdp1− /− complemented with hTDP1). 
Isoeugenol annotated as compound 14 revealed the highest, reproducible cytotoxic effect (p < 0.001, 4 nM; 
p < 0.05, 1 nM) when combined with CPT on Tdp1− /− cells but not on cells complemented with human TDP1, 
wherein the viability dropped from 65.5% (CPT alone) to 34.6% (CPT plus isoeugenol) at 4 nM CPT, and a 
reduction of ~18.2% at 1 nM CPT (Fig. 1G and Supplementary Fig. 4F). These results indicate that isoeugenol 
Compound Name Class CAS number Selected sublethal dose [μM]
1 Caffeic acid Phenolic acid 331–39–5 10
2 Khellin Chromone 82–02–0 10
3 p–Coumaric acid Phenolic acid 7400–08–0 10
4 Prunetin Flavonoid 552–59–0 10
5 Allyl anthranilate Terpenoid 7493–63–2 50
6 Cynarin Phenolic acid 1182–34–9 1
7 Caffiene Alkaloid 58–08–2 10
8 Isoquercitrin Flavonoid 482–35–9 10
9 Umbelliferone Coumarin 93–35–6 10
10 2,4,4′ trihydroxy chalcone Flavonoid 961–29–5 5
11 Emodin Anthraquinone 518–82–1 10
12 Chrysin Flavonoid 480–40–0 10
13 Sennoside A Anthraquinone 81–27–6 10
14 Isoeugenol Phenylpropanoid 97–54–1 50
15 Pseudoephedrine Alkaloid 90–82–4 10
16 Glycyrrhizin Saponin 1405–86–3 1
17 Epicatechin Flavonoid 490–46–0 5
18 Rutin Flavonoid 153–18–4 5
19 Vanillin Phenylpropanoid 121–33–5 10
20 Gallic acid Phenolic acid 149–91–7 1
21 Xanthohumol Flavonoid 6754–58–1 0.1
22 Glycyrrhetinic acid Terpenoid 471–53–4 10
23 Naringenin Flavanoid 67604–48–2 10
24 Harmine Alkaloid 442–51–3 0.1
25 Luteolin Flavonoid 491–70–3 10
26 Kaempferol Flavonoid 520–18–3 10
27 Hesperidin Flavonoid 520–26–3 10
28 Bisabolene Terpenoid 17627–44–0 0.01
29 α –ionone Terpenoid 127–41–3 0.01
30 cis–3–Hexenyl acetate Terpenoid 3681–71–8 0.01
31 α –Pinene Terpenoid 80–56–8 50
32 Cuminaldehyde Phenylpropanoid 122–03–2 50
33 Thymol Phenylpropanoid 89–83–8 50
34 Caryophyllene oxide Terpenoid 17627–43–9 50
35 Carvone Terpenoid 99–49–0 50
36 Dimethyl Disulphide Sulphur compound 624–92–0 0.01
37 Amentoflavone Flavonoid 1617–53–4 1
38 Sarcophine Terpenoid 55038–27–2 0.01
39 Chlorogenic acid Phenolic acid 327–97–9 10
40 Vitexin Flavonoid 3681–93–4 10
41 Quercetin Flavonoid 117–39–5 1
Table 1.  A list of the compounds employed in the screen.
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(4-propenyl-2-methoxyphenol), at 1 nM, does not exhibit a cytotoxic effect as a single agent, but rather holds a 
synergistic effect when combined with CPT in a TDP1-dependent manner. This was not an epiphenomenon of 
DT40 cells since isoeugenol also sensitized TDP1 depleted human MCF-7 cells to CPT, although the effect was 
much less apparent than DT40 cells (Supplementary Fig. 5).
Isoeugenol does not act through the PARP1/TDP1 axis. This data suggest that isoeugenol sensitizes 
cells to CPT only if TDP1 is absent, and that it may suppress TDP1 parallel pathways for repairing TOP1-induced 
PDBs. To further ascertain that the observed effects are independent of TDP1, we next examined the effect of 
isoeugenol on TDP1 catalytic activity using an in vitro biochemical assay employing a 13-mer oligonucleotide 
Cy5.5-labelled substrate containing a 3′ -phosphotyrosine modification. TDP1, in the reaction mixture, cleaves 
tyrosine from the substrate allowing it to move faster and further through the gel, giving a slightly shifted band. 
As a positive control, total cell lysate from wild-type DT40 cells was used as a source of TDP1 while Tdp1− /− cell 
lysate was used as a negative control. Different concentrations of isoeugenol (200 μ M, 500 μ M, and 1000 μ M) 
were incubated with the 3′ -phosphotyrosine substrate along with the cell lysates and reaction products were frac-
tionated by denaturing PAGE and analysed by fluorescence imaging. The addition of isoeugenol to the reaction 
did not inhibit the conversion of 3′ -PY substrate to 3′ -P (indicated by arrows) even at the highest concentration 
(1000 μ M), confirming that isoeugenol does not inhibit TDP1 activity (Fig. 2A,B). We reasoned that if isoeugenol 
potentiates CPT cytotoxicity independently of TDP1 one would predict that co-addition of PARP1 inhibitors 
would be epistatic to isoeugenol, since PARP1 and TDP1 are working together in the same pathway for TOP-PDB 
repair. To test this hypothesis, we compared the viability of Tdp1− /− cells and controls following CPT treat-
ment in presence and absence of isoeugenol and the FDA approved PARP inhibitor olaparib, either separately 
or in combination. Addition of olaparib to TDP1 proficient cells led to a marked increase in CPT cytotoxicity 
(Fig. 2C, p < 0.01). Importantly, co-addition of isoeugenol and olaparib did not further sensitise cells to CPT 
than addition of olaparib alone (Fig. 2C). In contrast to Tdp1 proficient cells, addition of olaparib to Tdp1− /− 
cells did not result in additional sensitisation, confirming that TDP1 and PARP1 operate in the same pathway 
(Fig. 2D). Notably, whilst addition of isoeugenol alone sensitized Tdp1− /− cells to CPT (p < 0.05), co-addition 
of isoeugenol did not. Together, we conclude from these findings that isoeugenol potentiates CPT cytotoxicity 
independently of the TDP1/PARP1 axis.
Figure 2. Isoeugenol does not inhibit TDP1 catalytic activity. (A) In vitro assay assessing the inhibitory effect 
of isoeugenol on TDP1. Isoeugenol concentrations of 200 μ M, 500 μ M, and 1000 μ M were incubated with the 
3-phosphotyrosine substrate and DT40 cell lysate (14 μ g). Reaction mixture was fractionated on denaturing 
PAGE and analysed by a ChemiDoc™ MP Imaging System. Arrows point at the position of substrate (PY) and 
cleaved product (P). (B) Bands were quantified using ChemiDoc™ MP Imaging System software and the average 
% substrate remaining of three independent experiments ± s.e.m. is shown. (C,D) Viability of Tdp1− /− DT40 
cells complemented with hTdp1 or Tdp1− /− DT40 cells following incubation with increasing concentrations 
of CPT alone or in the presence of the PARP inhibitor olaparib (0.1 μ M) with and without isoeugenol (50 μ M). 
Results are presented on a semi-log scale and represent the average of 3 biological replicates ± s.e.m. Asterisks 
denote statistical difference (hTDP1: p < 0.01, 10 nM and 15 nM; p < 0.001, 20 nM; Tdp1− /− : p < 0.05, 10 nM 
and 15 nM using t-test).
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Isoeugenol does not increase single-strand break (SSB) accumulation in CPT-treated cells. It 
is known that TDP1 deficient cells accumulate higher levels of DNA single-strand breaks (SSBs) in the presence 
of TOP1 inhibitors than controls14–17. We therefore examined if isoeugenol would increase the level of DNA 
strand breaks observed in Tdp1− /− DT40 cells, using alkaline single-cell gel electrophoresis (comet assays). As 
expected, the lack of TDP1 caused a CPT-dependent increase in SSB accumulation (P < 0.05); yet, isoeugenol did 
not potentiate such effect neither alone nor in combination with CPT (Fig. 3).
Isoeugenol inhibits TDP2 catalytic activity in vitro and potentiates the cytotoxic effect of 
etoposide in vivo. We previously reported that TDP2 could protect from TOP1-induced damage in the 
absence of TDP118. Consequently, we examined whether or not isoeugenol would inhibit TDP2 activity, poten-
tially providing a mechanistic insight explaining our data. Whole cell lysate from wild-type DT40 was employed 
Figure 3. Isoeugenol does not increase SSB accumulation in CPT- treated cells. (A) The indicated cell lines 
were incubated with 50 μ M CPT for 30 min or 50 μ M isoeugenol for 48 h or both at 37 °C. DNA strand breakage 
was quantified using alkaline comet assays. (B) Representative scatter plots of 150 cells (cells numbered from 
0 to 150) of CPT-treated or untreated cells with and without isoeugenol. Average tail moments from 150 cells 
per sample were measured, and data are the average of three independent biological replicates ± s.e.m. Asterisk 
denotes statistical difference (P < 0.05; t-test) between CPT TDP1− /− and CPT hTDP1 cells.
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as the source for TDP2. Incubation of 5′ -phosphotyrosine substrate with increasing concentrations of isoeuge-
nol revealed a dose-dependent reduction in the conversion of 5′ -PY to 5′ P, which is specific for TDP2 activity 
(Fig. 4A). Whilst incubation with extract alone led to ~50% processing, co-addition of 200 μ M isoeugenol sup-
pressed TDP2 activity resulting in ~34% processing (Fig. 4B). Increasing the concentration of isoeugenol to 500 μ 
M and 1000 μ M showed a corresponding increase in the inhibition of TDP2 activity reaching as little as 6% or no 
conversion, respectively. The putative TDP2 inhibitory effect of isoeugenol was not due to the vehicle in which 
it was dissolved (DMSO) since we kept the concentration of DMSO constant in all control and test conditions. 
These observations suggest that isoeugenol inhibits chicken TDP2 catalytic activity at high doses. To test if this 
is an epiphenomenon for chicken DT40 or is also true in human cells, we repeated the experiments using HeLa 
cell lysates (Fig. 4C). Consistent with its TDP2 inhibitory activity, isoeugenol also inhibited human TDP2 but 
less efficiently than chicken TDP2 with only 20% inhibition at the highest isoeugenol dose examined (1000 μ M). 
If isoeugenol inhibits TDP2 activity we reasoned that it would sensitize human cells to TOP2 poisons, which 
specifically require TDP2 to liberate stalled TOP2 from DNA termini. Incubation with etoposide led to a dose 
dependent decline in viability of both HeLa and MCF7 cells and the co-addition of isoeugenol resulted in further 
sensitisation (Fig. 4E,F). At 50 μ M etoposide, the viability of HeLa and MCF-7 cells dropped, upon the addition 
of isoeugenol, from 94.8% to 64.1% and from 91.1% to 72.1%, (P < 0.001, P < 0.05; resp.). At a higher dose of 
100 μ M etoposide, viability of HeLa cells decreased from 75.5% to 49.6%, and from 91.2% to 56.9% for MCF-7 
cells (P < 0.01). Importantly, addition of low micromolar doses of isoeugenol (1 μ M) sensitized HeLa cells to all 
concentrations of etoposide tested, as measured by clonogenic survival assays (Fig. 4G). Together, these findings 
identify isoeugenol as a promising lead compound with potential TDP2 inhibitory activity.
Discussion
Drug combination therapy is a promising strategy used in treating complex diseases such as cancer, cardiovas-
cular diseases, and infectious diseases19. Synergistic drug combinations are recognized as effective and thera-
peutically specific20. Overcoming toxicity, side effects linked to high doses of single drugs, and drug resistance 
can be achieved by synergistic combinations of two or more agents. Consequently, this study aimed to achieve 
a synergistic therapeutic effect and minimize dose through combination between the TOP1 inhibitor CPT and 
natural compounds. Screening of 41 compounds from natural origin belonging to diverse classes of natural prod-
ucts viz. alkaloids, phenylpropanoids, saponins and terpenes in combination with CPT revealed a synergistic 
effect between the phenolic ether isoeugenol and CPT against Tdp1− /− DT40 cells. Such a synergistic effect 
encourages further research and may lead to a new anti-cancer strategy that target a specific class of tumors, such 
as those that develop resistance to camptothecins, for example colorectal cancers (CRCs). Our screen identified 
isoeugenol, a phenylpropanoid, as a compound that potentiates CPT cytotoxic effect on cells that lack TDP1. 
Several studies have shown that phenylpropanoids exhibit different biological activities that include analgesic, 
anti-inflammatory, and anti-tumor activities21–23. Isoeugenol (4-propenyl-2-methoxyphenol) is abundantly pres-
ent in several plant essential oils and is regularly used in spices, perfumes, and detergents, thus is unlikely to 
exert toxic effects on humans24. It is a structural isomer of eugenol found in clove and cinnamon oil and is mostly 
recognized medicinally for its local anesthetic effect25. Notably, previous studies have shown that eugenol exhibits 
a topoisomerase II (TOP2) inhibition activity26,27, however, to the best of our knowledge, there are no studies 
conducted on isoeugenol. Eugenol was found to display genotoxic activity via TOP2 inhibition, halting cells in 
the replication phase, causing S-phase arrest and apoptosis. In addition, eugenol upregulates numerous enzymes 
involved in the base excision repair pathway and E2F family members in addition to its potential synergistic effect 
with gemcitabine and fluorouracil on HeLa cells26.
In an attempt to examine the mechanism through which isoeugenol potentiates CPT cytotoxic effect on 
TDP1-deficient cells, we have conducted a series of cellular and biochemical experiments to test specific PDB 
repair pathways. First, the PARP1-TDP1 pathway was assessed. PARP1 directs TDP1 towards the break induced 
by CPT, where TDP1 cleaves the bond between TOP1 and the DNA 3′ -terminus. This is followed by modification 
in the 3′ - and 5′ -termini via polynucleotide kinase phosphatase (PNKP), and finally ligation by DNA Ligase III 
(Lig3α )28. Our findings suggest that isoeugenol potentiates CPT cytotoxicity independently of TDP1 for multiple 
reasons. First, only TDP1 deficient, but not proficient, cells were responsive to isoeugenol. Second, biochemical 
analyses failed to detect inhibitory effect of isoeugenol on established TDP1 substrates. Third, isoeugenol did not 
further sensitise CPT-treated cells to the PARP1 inhibitor olaparib. It is possible that isoeugenol targets a parallel 
nucleolytic pathway or another tyrosyl DNA phosphodiesterase that has been implicated for TOP1-mediated 
PDB repair, particularly in absence of TDP1. Our data favors the latter possibility since isoeugenol displayed 
detectable TDP2 inhibitory activity in vitro when incubated with cell lysates from Chicken DT40 or HeLa cells. 
These observations were further supported by a significant potentiation of cytotoxicity inflicted by the TOP2 
poison etoposide, which specifically generates TOP2-mediated PDBs for which TDP2 is required for processing.
TDP2′ s discovery as a 5′ -tyrosyl DNA phosphodiesterase in 200929 has since impelled scientists to search for 
an inhibitor. It has been proposed that drug resistance to TOP2 inhibitors, such as etoposide, may stem from an 
acquired or intrinsic overexpression in TDP2, which as discussed earlier guards against the abortive activity of 
TOP2 during replication and transcription. In 2013, Oglivie et al. have managed to uncover two classes of com-
pounds, toxoflavins and deazaflavins, as selective TDP2 inhibitors following a high-throughput screening30. More 
recently, isoquinoline-1,3-diones was also found to selectively inhibit TDP2 at a low micromolar concentration31. 
Isoeugenol exhibits a dose dependent inhibitory activity on TDP2, but not TDP1, albeit at higher concentrations. 
Notably, vanillin (4-hydroxy-3-methoxybenzaldehyde) a structural analogue for isoeugenol (Supplementary Fig. 5) 
that only differs in an aldehyde group instead of a prop-1-ene moiety displayed no activity in our assays, sug-
gesting that the presence of an alkenyl group is crucial for biological activity. In planta, there exists several other 
isoeugenol analogues particularly found in spices and medicinal herbs such as eugenol anethole, estragole, saf-
role, myristicin, and methyl isoeugenol, all of which have yet to be assessed and might provide more potent 
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Figure 4. Isoeugenol inhibits TDP2 catalytic activity in vitro and potentiates etoposide cytotoxic effect 
in vivo. (A) Wild-type DT40 cell lysate was incubated with DMSO or with the indicated concentrations of 
isoeugenol. Reaction products were resolved by denaturing PAGE and analysed by fluorescence imaging. 
Arrows point at the position of substrate (PY) and cleaved product (P). (B) The bands from A were quantified 
using ChemiDoc™ MP Imaging System software and the average % substrate remaining of three independent 
experiments ± s.e.m is shown. Asterisks denote statistical difference (p < 0.01, 1000 μ M and 500 μ M; p < 0.05, 
200 μ M) using t-test between DMSO and each concentration. (C) HeLa cell lysate was incubated with DMSO 
or with the indicated concentrations of isoeugenol and reaction products analysed as described in A,B. 
(D) The bands were quantified using ChemiDoc™ MP Imaging System software and the average of % substrate 
remaining for three independent experiments ± s.e.m is shown. Asterisks denote statistical difference (p < 0.01, 
1000 μ M; p < 0.05, 500 μ M and 200 μ M) using t-test between DMSO and each concentration. Viability of HeLa 
(E) and MCF-7 (F) cells was compared using the indicated doses of etoposide (sub-lethal: 50, 25, 10, and 5 μ 
M; lethal: 100 μ M) in the presence and absence of sub-lethal doses of isoeugenol (200 μ M and 400 μ M for 
Hela and MCF-7; resp.). Results are represented on a semi-log graph and present the average of 3 biological 
replicates ± s.e.m. Asterisks denote statistical difference (p < 0.001, p < 0.05 at 50 μ M for HeLa and MCF-7, 
resp.; p < 0.01 at 100 μ M for both cell lines) using t-test. (G) HeLa cells were treated with the indicated doses of 
etoposide in the absence or presence of 1 μ M isoeugenol for 10 days and the number of surviving colonies was 
counted and presented as % survival. Data are the average of 3 biological replicates ± s.e.m. Asterisks denote 
statistically significant difference between etoposide alone and etoposide in combination with isoeugenol 
(P < 0.01, 0.001, 0.01, 0.05 and 0.001 for doses 1, 0.7, 0.5, 0.3, 0.2 μ M; resp.).
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drug candidates. Finally, We noted that the effect of isoeugenol on Tdp1− /− DT40 cells was more prominent 
compared to TDP1 depleted human cells. This may reflect residual TDP1 in human cells, due to siRNA knock-
down versus genetic disruption in DT40 cells, which is sufficient to mask the requirement for alterative pathways 
(i.e. TDP2). Alternatively, it could reflect the differential inhibition of chicken and human TDP2 by isoeugenol. 
In support of the latter possibility, incubation of 500 μ M isoeugenol with DT40 cell extract nearly reached full 
inhibition with ~100% substrate remaining (Fig. 4A,B) versus ~80% for HeLa cell extract (Fig. 4C,D). These 
observations point at cross species differences, which may be illuminating in future studies aiming at improving 
the potency of isoeugenol as a candidate for drug discovery.
In summary, we identify isoeugenol as a potentiator of CPT cytotoxicity in a TDP1 dependent manner and 
suggest that it acts by inhibiting TDP2 activity. Isoeugenol therefore may act as a potential lead compound 
for developing TDP2 inhibitors. Future structure-activity relationship studies might be warranted to improve 
potency and shed light on its utility in drug discovery programs.
Materials and Methods
Chemicals. Caffeic acid, p-Coumaric acid, naringinen, chlorogenic acid, quercetin, isoquercetin, umbel-
liferone, harmine, luteolin, caffeine, 2,4,4′ -trihydroxy chalcone, naringinin-7-glucoside, pseudoephedrine, gly-
cyrrhizin, epicatechin, vanillic acid, gallic acid, β -glycyrrhetenic acid, xanthohumol and amentoflavone were 
purchased from Sigma Aldrich (St. Louis, MO, USA). Bisabolene, α -ionone, (Z)-3-hexenyl acetate, allyl anthra-
nilate, isoeugenol, α -pinene, cuminaldehyde, thymol, caryophyllene oxide, carvone, and methyl disulphide were 
provided from Bedoukian Research (Danbury, CT, USA). Cynarin, emodin, rutin, and sennoside A were pur-
chased from Chromadex (Wesel, Germany). Khellin was a gift from Prof. Dieter Treutter (Tech Univ. of Munich, 
Germany). Sarcophine was isolated from Sarcophyton ehrenbergi soft coral whereas vitexin and chrysin were 
isolated from Passiflora edulis leaf in Dr. Farag laboratory, Cairo University (Supplementary Fig. 6).
Cell culture. Tyrosyl-DNA phosphodiesterase 1-knockout DT40 cells (Tdp1− /− ) and those complemented 
with human TDP1 (hTDP1) were cultured at 37 °C and 5% CO2 (NuAire) in RPMI 1640 medium (Lonza) sup-
plemented with 7% FBS (Sigma), 3% chicken serum (Sigma), 1% L-glutamine (Lonza), and 1% penicillin/strepto-
mycin (Lonza). These cell lines have been previously reported and described18. HeLa and MCF-7 cells were grown 
in Dulbeco’s Modified Eagle’s Medium (DMEM) (lonza) supplemented with 10% FBS (Sigma), 1% L glutamine 
(Lonza), and 1% penicillin/streptomycin (Lonza) at 37 °C and 5% CO2.
Viability assays and clonogenic survival. The compounds were screened on both DT40 Tdp1− /− and 
DT40 Tdp1− /− complemented with hTDP1. Cells were seeded into 96-well plates at a density of 3000 cell/well 
on day 0. The compounds, CPT (Sigma), and other inhibitors were added at varying concentrations in triplicate. 
On day 2, 20 μ l cell-titer blue (Promega) was added and the plate incubated at 37 °C. After 4 hours, the viability 
was quantified as fluorescence intensity using a microplate reader, FLUOstar Omega (BMG LABTECH). Olaparib 
(MedKoo Biosciences) and isoeugenol (0.1 and 50 μ M, resp.) were co-added along with increasing concentrations 
of CPT to DT40 cells (2000 cell/well). After a 72-hour incubation, viability was assessed using the cell-titer blue 
kit as above. HeLa and MCF-7 cells (5000 cell/well) were treated with five doses of etoposide (Sigma) one lethal 
(100 μ M) and four sub-lethal doses (50, 25, 10, and 5 μ M)in the presence or absence of sub-lethal doses (200 
and 400 μ M for HeLa, MCF-7; resp.) of isoeugenol in triplicate. Treated cells were incubated at 37 °C for 48 h 
and cell viability measured using the cell-titer blue. Two hundred HeLa cells were seeded in 6 cm dishes at 37 °C 
overnight. Cells were treated with DMSO (Sigma) or indicated doses of etoposide (1, 0.7, 0.5, 0.3, 0.2 µM) in the 
presence or absence of isoeugenol (1 μM) . Cells were allowed to grow for 10 days. Visible colonies were stained 
and survival calculated a described below. MCF-7 cells were transfected using siPORT™ NeoFX™ (Invitrogen) 
transfection reagent with siRNA at a final concentration of 100 nM. The siRNA sequences that were used to target 
TDP1 are 5′ -CUAGACAGUUUCAAAGUGA-3′ 5′ -UCACUUUGAAACUGUCUAG-3′ , 5′ -GACCAUAUCUA 
GUAGUGAU-3′ 5′ -AUCACUACUAGAUAUGGUC-3′ , 5′ -UCAGUUACUUGAUGGCUUA-3′ 5′ -U 
AAGCCAUCAAGUAACUGA-3′ , and 5′ -GGAGUUAAGCCAAAGUAUA-3′ 5′ -UAUACUUUGGCUU 
AACUCC-3′ , and for scrambled siRNA control, 5′ -GCGCGCUUUGUAGGAUUCG-3′ 5′ -CGAAUCCUACAAA 
GCGCGC-3′ was used. Cells were incubated at 37 °C for 24 h then the media replaced with complete media and 
incubated for an additional 24 h. One hundred MCF-7 cells were seeded in 6 cm dishes at 37 °C overnight. Then 
cells were treated with DMSO (Sigma) or indicated doses of CPT in the presence or absence of isoeugenol (4 μ 
M) in triplicate. Cells were allowed to grow for 14 days. Colonies were fixed with 75% methanol and stained with 
1% Giemsa stain. The surviving fraction was calculated as ((colonies counted/total cells seeded)treated/(colonies 
counted/total cells seeded)untreated).
Western Blot. Cells were lysed in lysis buffer (10 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L 
EDTA, 0.5% NP40, 50 mmol/L NaF, 1 mmol/L phenylmethylsulfonyl fluoride, and 1 mmol/L Na3 VO4). Total 
protein concentration was determined using Bradford assay, and equal amounts of total protein were then boiled 
at 95 °C for 5 min with SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (25% glycerol, 31.2 ml 
0.25 M Tris-HCl (pH 6.8), 7.5 ml 10% SDS, 0.3 M DTT and a dash of bromophenol blue/100 ml) and separated by 
11% SDS-PAGE. Separated proteins were then transferred onto apolyvinylidene difluoride (PVDF) membranes 
(Millipore) following standard methods. The membranes were incubated in blocking solution (2% non-fat milk 
in PBS) for 1 h, further incubated with primary antibodies (mouse monoclonal anti-TDP1 (Santa Cruze; cat 
no. Sc-365674) at a dilution of 1:500 and anti-human beta actin at a dilution of 1:1000) overnight at 4 °C, and 
then incubated with a secondary antibody (anti-mouse horseradish peroxidase, (HRP)-linked IgG antibody at 
a dilution of 1:1000 for TDP1 and beta actin) (Invitrogen) for 1 h at room temperature. After 3 × 10-min washes 
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in T-PBS (0.1% Tween-20 in PBS) the membranes were developed with enhanced chemiluminescence detection 
reagent, clarity™ western ECL blotting substrate (Biorad). Signal on membranes was obtained using ChemiDoc™ 
MP Imaging System (Biorad).
TDPs activity assay: Gel-based assay. The in vitro 3′ -tyrosyl-DNA phosphodiesterase 1 and 2 
inhibitory activity of compound 14 (200 μ M, 500 μ M, and 1000 μ M) was determined using a gel-based 3′ - 
tyrosyl-DNA phosphodiesterase activity assay. Biochemical assays were performed in 10 μ L reaction volumes 
containing TDP1 reaction buffer (50 mM Tris HCL (pH 7.5), 50 mM KCl, 1 mM DTT, 10 M EDTA, and 100 μ g/ml 
BSA) or TDP2 reaction buffer (50 mM Tris HCL (pH 7.5) 50 mM KCl, 1 mM DTT, 100 μ g/ml BSA, and 
1 mM MgCl2), cell lysate (14 ≈ 16 μ g , TDP1; 14 μ g TDP2), and 50 nM Cy5.5-labelled substrate oligomer 5′ - 
(Cy5.5)GATCTAAAAGACT(pY)-3′ (Midland Certified Reagent Company, Texas, USA) for TDP1 or 5′ -(pY)
CATCGTTGCCTACCAT(Cy5)-3′ for TDP2. The reactions progressed at 37 °C for 2 h (TDP1) and 1 h (TDP2) 
and were quenched with 10 μ L loading buffer (44% deionized formamide, 2.25 mM Tris-borate, 0.05 mM EDTA, 
0.01% xylene cyanol, and 1% bromophenol blue). Samples were then heated at 90 °C for 10 min prior to separa-
tion on a 20% urea SequaGel by gel electrophoresis at 100 V for 30 min. Reaction products were visualized by gel 
imaging using ChemiDoc™ MP Imaging System (Biorad)32.
Alkaline single-cell agarose gel electrophoresis assay. Cells were plated and incubated at a density 
of 60,000 cell/well with 50 μ M CPT for 30 min, 50 μ M of compound 14, or CPT plus compound 14 at 37 °C for 
48 h. DNA strand breakage, primarily (SSBs) and alkali-labile sites, were quantified by alkaline comet assays as 
described in33. Briefly, cells were suspended in pre-chilled phosphate buffered saline (PBS) and mixed with equal 
volume of 1.3% low-gelling-temperature agarose (Sigma, Type VII) maintained at 42 °C. Cell suspension was 
immediately layered onto pre-chilled frosted glass slides (Fisher), pre-coated with 0.6% agarose. The slides were 
maintained in the dark at 4 °C until set, and for all further steps. Slides were immersed in pre-chilled lysis buffer 
(2.5 M NaCl, 10 mM Tris-base, 100 mM EDTA (pH 8.0), 1% Triton X-100, and 10% DMSO; (pH 10.0)) for 1 h, 
washed with pre-chilled distilled water (2–10 min), and placed for 30 min in pre-chilled alkaline electrophoresis 
buffer (50 mM NaOH and 1 mM EDTA). Electrophoresis was then conducted at 1 V/cm for 30 min, followed by 
neutralization in 400 mM Tris- HCl (pH 7.0) for 1 h. Finally, DNA was stained with Sybr Green I nucleic (Sigma) 
(1:10000, in PBS) for 30 min. Average tail moments from 150 cells per sample were measured using Comet Assay 
IV software (Perceptive Instruments, UK)16.
Statistical analysis. All statistical parameters were performed using excel version 2013 (Microsoft office). 
Viability was calculated by dividing the mean of treated cells by the untreated cells. Average tail moments from 
150 cells per sample were measured using Comet Assay IV software (Perceptive Instruments, UK). All data are 
presented as means with conforming SEM of three biological triplicates. Student′ s t-test was used to compare cell 
viability and tail moment between compounds, CPT alone, and combination with different concentrations of 
CPT. In all tests, the level of significance was set at p < 0.05.
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